KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire
Thoracic endometriosis presenting with bilateral haemothoraces: a rare but important cause of bilateral pleural effusions.
A woman in her 30s was admitted with 6 months of progressive shortness of breath and cyclical bilateral pleuritic chest pain associated with heavy, painful menstruation. She had a history …
Yiqi Huoxue Formula ameliorates endometriosis by suppressing NF-κB p65/NLRP3 inflammasome-associated pyroptotic signaling.
Yiqi Huoxue Formula (YQHXF) is an 11-herb hospital-based traditional Chinese medicinal formula developed according to the therapeutic principle of tonifying qi and activating blood circulation. Previous clinical application has suggested …